Has secondary leukaemia been reported after treatment with idarubicin hydrochloride?

Yes, secondary leukaemia, with or without a preleukemic phase, has been reported with idarubicin hydrochloride and can have a 1–3-year latency; it is more common with DNA-damaging antineoplastic combinations, heavy prior cytotoxic treatment, or escalated anthracycline doses.